Torsade de Pointes

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 687-699

  El Sherif, Nabil ^a   Turitto, Gioia ^b  

^a SUNY Downstate Medical Center   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845772917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50077-4     Document Type: Chapter

References (40)

1. Dessertenne F La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur 1996, 59:263-272.
2. El-Sherif N, Turitto G The long QT syndrome and torsade de pointes. PACE 1999, 22:91-110.
3. Zareba W, Moss AJ Long QT syndrome in children. J Electrocardiol 2001, 34:167-171.
4. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000, 102:1178-1184.
5. Castillo R, Pedalino RP, El-Sherif N, Turitto G Efavirenz-associated QT prolongation and Torsade de pointes arrhythmia. Ann Pharmacother 2002, 36:1006-1008.
6. Canadian Adverse Drug Reaction Newsletter Drugs causing prolongation of QT interval and torsade de pointes. Can Med Assoc J 1998, 158:103-104.
7. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000, 11:691-696.
8. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000, 97:10613-10618.
9. Moss AJ, Zareba W, Benhorin J, et al. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: Task Force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol 2001, 6:333-341.
10. El-Sherif N, Zeiler RH, Craelius W, et al. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Circ Res 1988, 63:286-305.
11. El-Sherif N, Fozzard HA, Hanck DA Dose-dependent modulation of the cardiac sodium channel by the sea anemone toxin ATXII. Circ Res 1992, 70:285-301.
12. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
13. Bennett PB, Yazawa K, Makita N, George AL Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995, 376:683-685.
14. El-Sherif N, Caref EB, Yin H, Restivo M The electrophysiological mechanism of ventricular tachyarrhythmias in the long QT syndrome: Tridimensional mapping of activation and recovery patterns. Circ Res 1996, 79:474-492.
15. El-Sherif N, Chinushi M, Caref EB, Restivo M Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long QT syndrome. Detailed analysis of ventricular tridimensional activation patterns. Circulation 1997, 96:4392-4399.
16. Chinushi M, Restivo M, Caref EB, El-Sherif N Electrophysiological basis of the arrhythmogenicity of QT/T alternans in the long QT syndrome. Tridimensional analysis of the kinetics of cardiac repolarization. Circ Res 1998, 83:614-628.
17. El-Sherif N, Caref EB, Chinushi M, Restivo M Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol 1999, 33:1415-1423.
18. Antzelevich C, Sicouri S Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994, 23:259-277.
19. Kozhevnikov DO, Yamamoto K, Robotis D, et al. Electrophysiological mechanisms of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias. Tridimensional mapping of activation and recovery patterns. Circulation 2001, 105:1128-1134.
20. Mazur A, Anderson ME, Bonney S, et al. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: A placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 2001, 37:1100-1105.
21. Leclercq JF, Maison-Blanche P, Cauchemez B, Coumel P Respective role of sympathetic tone and cardiac pauses in the genesis of 62 cases of ventricular fibrillation recorded during Holter monitoring. Eur Heart J 1988, 9:1276-1283.
22. Viskin S, Alla SR, Barron HV, et al. Mode of onset of torsades de pointes in congenital long QT syndrome. J Am Coll Cardiol 1996, 28:1262-1268.
23. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsades de pointes; the long-short initiating sequence and other clinical features; observations in 32 patients. J Am Coll Cardiol 1990, 2:806-817.
24. El-Sherif N, Turitto G, Pedalino RP, Robotis D T-wave alternans and arrhythmia risk stratification. Ann Noninvas Electrocardiol 2001, 6:323-332.
25. Shimizu W, Antzelevich C Cellular and ionic basis for T-wave alternans under long QT conditions. Circulation 1999, 99:1499-1507.
26. Pastore JM, Girouard SD, Laurita KR, et al. Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. Circulation 1999, 99:1385-1394.
27. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995, 92:3381-3386.
28. Schreick J, Wang Y, Gjini V, et al. Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol 1997, 8:1420-1430.
29. Noda T, Takaki H, Kurita T, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Eur Heart J 2002, 23:975-983.
30. Vincent GM, Timothy K, Leppert M, Keating MV The spectrum of symptoms and QT interval in carriers of the gene for the long-QT syndrome. N Engl J Med 1992, 327:846-852.
31. Vincent GM, Fox J, Zhang L, Timothy KW Beta-blockers markedly reduce risk and syncope in KVLQT1 long QT patients. Circulation 1996, 94(suppl 1):1-204.
32. + channel blockade and to increase in heart rate. Implications for gene-specific therapy. Circulation 1995, 92:3381-3386.
33. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996, 94:1018-1022.
34. Vincent GM, Fox J, Zhang L, et al. Effects of a potassium channel opener in KVLQT1 long QT gene carriers. J Am Coll Cardiol 1997, 29:183A.
35. Shimuzu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995, 26:1299-1309.
36. Roden DN, Woosley RL, Prim RK Incidence and clinical features of the quinidine associates long QT syndrome: Implications for patient care. Am Heart J 1986, 111:1088-1093.
37. Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsade de pointes. Am J Cardiol 1984, 53:528-530.
38. Wolfe CL, Nibley C, Bandhari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991, 84:1543-1551.
39. Brugada P, Brugada J Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 1992, 20:1391-1396.
40. Priori S, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106:8-10.